VK2735: Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •6 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (4 countries listed)
Risk Assessment
VK2735 is not approved by any regulatory authority. It is currently in Phase 3 clinical trials (VANQUISH program). The full safety profile is not yet established.
As a GLP-1 receptor agonist, VK2735 is expected to carry the GLP-1 class warning for thyroid C-cell tumors observed in rodent studies. Contraindicated in patients with MTC or MEN2 history.
GI adverse events are the most common side effects. In Phase 2, 95% of treatment-emergent adverse events were GI-related. Most were mild to moderate but may cause dehydration in some patients.
GLP-1 receptor agonists as a class are associated with pancreatitis risk. Patients should report persistent severe abdominal pain immediately.
Significant weight loss (14.7% at 13 weeks in Phase 2) increases the risk of cholelithiasis and cholecystitis.
Only Phase 2 data (13 weeks, approximately 350 patients total) are available. Phase 3 data from over 4,500 patients will provide a more comprehensive safety profile.
⚠️Important Warnings
- •INVESTIGATIONAL AGENT: VK2735 is not approved by any regulatory authority. It should only be used within approved clinical trials.
- •EXPECTED GLP-1 CLASS WARNING: VK2735 is expected to carry the thyroid C-cell tumor warning. Do not use in patients with MTC or MEN2 history.
- •GI adverse events are very common (95% of TEAEs in Phase 2 were GI-related). Most are mild to moderate. Maintain adequate hydration.
- •Do not use during pregnancy. GLP-1 receptor agonists should be discontinued before planned conception.
- •No cardiovascular outcomes data are available. Long-term cardiovascular safety has not been established.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Investigational | Phase 3 VANQUISH trials underway. Not FDA-approved. No NDA filed yet. |
| European Union | Investigational | Not EMA-approved. Regulatory pathway anticipated following Phase 3 results. |
| United Kingdom | Investigational | Not MHRA-approved. No regulatory submission. |
| Canada | Investigational | Not Health Canada-approved. No regulatory submission. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
0View community protocolsCritical Safety Information#
VK2735 is an investigational dual GLP-1/GIP receptor agonist currently in Phase 3 clinical trials. It has not been approved by any regulatory authority. All safety information is derived from Phase 2 trials enrolling approximately 350 patients with a maximum treatment duration of 13 weeks. The full safety profile will be established through the ongoing Phase 3 VANQUISH program.
Investigational Status#
VK2735 is currently in Phase 3 development:
- VANQUISH-1: Over 4,500 patients enrolled
- VANQUISH-2: Additional Phase 3 trial
- No NDA filed: Regulatory filing will follow Phase 3 results
- Oral formulation: Phase 2 data available; Phase 3 planning ongoing
Until regulatory approval, VK2735 should only be used within approved clinical trials.
GLP-1/GIP Agonist Class Risks#
Thyroid C-Cell Tumors#
GLP-1 receptor agonists carry a class-wide boxed warning based on thyroid C-cell tumors observed in rodent studies with GLP-1 RAs. VK2735 is expected to carry similar warnings and contraindications. Patients with personal or family history of medullary thyroid carcinoma or MEN2 should not receive VK2735.
Pancreatitis#
GLP-1 agonists have been associated with pancreatitis. The dual GLP-1/GIP mechanism of VK2735 has not been specifically characterized with respect to pancreatitis risk. Patients should report persistent severe abdominal pain.
Gallbladder Disease#
The rapid and substantial weight loss produced by VK2735 (14.7% at 13 weeks) increases the risk of cholelithiasis and cholecystitis, consistent with rapid weight loss from any cause.
Acute Kidney Injury#
GI adverse events (nausea, vomiting, diarrhea) can cause dehydration, which may contribute to acute kidney injury.
Limited Long-Term Safety Data#
A significant risk factor for VK2735 is the limited duration and size of the current safety database:
| Parameter | Current Data |
|---|---|
| Maximum treatment duration | 13 weeks (Phase 2) |
| Total patients treated | Approximately 350 (Phase 2) |
| Phase 3 patients enrolled | Over 4,500 (results pending) |
| Cardiovascular outcomes data | None |
| Cancer surveillance | Limited by short duration |
Regulatory and Legal Status#
| Jurisdiction | Status | Notes |
|---|---|---|
| United States (FDA) | Investigational | Phase 3 VANQUISH trials underway |
| European Union (EMA) | Investigational | No regulatory submission |
| United Kingdom (MHRA) | Investigational | No regulatory submission |
| Canada (Health Canada) | Investigational | No regulatory submission |
At-Risk Populations#
Patients with MTC or MEN2 History#
Expected absolute contraindication based on GLP-1 agonist class labeling.
Pregnant and Breastfeeding Women#
GLP-1 receptor agonists carry pregnancy risks. Discontinue before planned conception.
Patients with Severe GI Disease#
The high rate of GI adverse events may be poorly tolerated by patients with gastroparesis or GI motility disorders.
Patients on Insulin or Sulfonylureas#
The GLP-1 receptor agonism may increase hypoglycemia risk when combined with insulin or insulin secretagogues.
Risk Mitigation#
- Use only within approved clinical trials until regulatory approval
- Screen for MTC/MEN2 history before enrollment
- Follow dose escalation schedule to minimize GI adverse events
- Maintain adequate hydration during treatment
- Monitor for pancreatitis and gallbladder symptoms
- Adjust insulin or sulfonylurea doses when initiating treatment
Related Reading#
Frequently Asked Questions About VK2735
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.